Intravesical cytosine arabinoside + Mitomycin C for bladder cancer – is it beneficial?

Mitomycin C (MMC) is often used as an intravesical therapy for low / intermediate risk non-muscle invasive bladder cancer. This randomised controlled trial (RCT) was designed to assess the safety and efficacy of MMC + cytosine arabinoside (Ara-C). Ara-C was an alkalinising agent with the rationale being evidence of increased tumour exposure of MMC in alkaline pH. Randomisation was performed prior…

Read the full article here

Source: Urology News
Categories: Latest Headlines, Urology
Tags: , , , ,
Tweets with this article
Urology News
#JournalReviews - A new clinical trial compares the effectiveness of Intravesical mitomycin C (#MMC) alone vs MMC + cytosine arabinoside in treating non-muscle-invasive bladder cancer 🔬💊💪 #BladderCancer https://t.co/oisycNvNLl #ClinicalTrial #CancerResearch

Related Articles